CEL-SCI is a biotechnology business based in the US. CEL-SCI shares (CVM) are listed on the NYSE MKT and all prices are listed in US Dollars. Its last market close was $0.25 – a decrease of 16.67% over the previous week.
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $0.25 |
|---|---|
| 52-week range | $0.18 - $2.39 |
| 50-day moving average | $0.28 |
| 200-day moving average | $0.69 |
| Wall St. target price | $8.00 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-0.48 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $0.25 from 2025-05-02
| 1 week (2025-04-25) | -13.79% |
|---|---|
| 1 month (2025-04-04) | 15.69% |
| 3 months (2025-02-05) | -37.34% |
| 6 months (2024-11-05) | -68.75% |
| 1 year (2024-05-03) | -84.66% |
|---|---|
| 2 years (2023-05-04) | -89.50% |
| 3 years (2022-05-04) | 3.14 |
| 5 years (2020-05-04) | 13.8 |
| Revenue TTM | $28,558 |
|---|---|
| Gross profit TTM | $-18,239,004 |
| Return on assets TTM | -61.48% |
| Return on equity TTM | -233.26% |
| Profit margin | 0% |
| Book value | $0.15 |
| Market Capitalization | $21.1 million |
TTM: trailing 12 months
We're not expecting CEL-SCI to pay a dividend over the next 12 months.
CEL-SCI's shares were split on a 1:25 basis on 14 June 2017 . So if you had owned 25 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your CEL-SCI shares – just the quantity. However, indirectly, the new 2400% higher share price could have impacted the market appetite for CEL-SCI shares which in turn could have impacted CEL-SCI's share price.
Over the last 12 months, CEL-SCI's shares have ranged in value from as little as $0.18 up to $2.39. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE MKT average) beta is 1, while CEL-SCI's is 0.953. This would suggest that CEL-SCI's shares are less volatile than average (for this exchange).
CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development to treat cancer and other diseases by using the immune system in the United States. The company's lead immunotherapy is Multikine, which has completed Phase III clinical trials for the potential treatment of certain head and neck cancers. It is also developing Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer, as well as to potentially treat rheumatoid arthritis. In addition, the company's LEAP product candidates include CEL-2000; CEL-4000; and CEL-5000 that are in preclinical trials for potential rheumatoid arthritis therapeutic treatments. CEL-SCI Corporation was incorporated in 1983 and is headquartered in Vienna, Virginia. .
Track the progress of the S&P 500 stocks to make more informed investment decisions.
See our picks for the best brokers for trading S&P 500 stocks, ETFs, options and futures.
These are the stocks to buy when you don’t have much to spend.
Explore the best bonuses for opening a new brokerage account.
Stock lending allows investors to loan out their existing stocks, although it has both advantages and disadvantages.
Compare pros, cons, research tools and reviews for these two trading platforms.
Some of the best trading apps like Robinhood are SoFi, Tastytrade, Public, eToro, Acorns, Interactive Brokers, E*TRADE and more.
Compare pros, cons, research tools and reviews for these two trading platforms.
SoFi Invest is a no-fee commissions platform with both active and automated investment accounts.
Webull is a broker with zero-commission trading and a suite of tools to help you invest.